GA
MDGL icon

Geller Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

Geller Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-5,352
Closed -$326K – 31
2015
Q3 		$326K Hold
5,352
– – 0.21% 20
2015
Q2 		$418K Hold
5,352
– – 0.24% 20
2015
Q1 		$363K Buy
+5,352
New +$459K 0.21% 22

Other funds holding MDGL

CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geller Advisors's MDGL Position: Q4 2015 in Review

Geller Advisors sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2015, closing a stake of 5,352 shares — an estimated $326K sold.

Geller Advisors first reported a position in MDGL in Q1 2015 and held it in 3 quarters. The position peaked at $418K in Q2 2015. 75 funds tracked by Wall St. Rank hold MDGL as of Q4 2015.

  • Geller Advisors reported no remaining Madrigal Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Geller Advisors sold 5,352 Madrigal Pharmaceuticals shares in Q4 2015, an estimated $326K.
  • Geller Advisors first reported a position in Madrigal Pharmaceuticals in Q1 2015 and held it in 3 quarters.
  • Geller Advisors's Madrigal Pharmaceuticals position peaked at $418K in Q2 2015.
  • 75 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2015.

Based on Geller Advisors's 13F filing for Q4 2015, filed 8 Feb 2016.